Sign in to view content

Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept

Mark R. Barakat, MD

Video
Published 2022

Related

Characteristics and Outcomes of nAMD Patients Managed in US Routine Clinical Practice: Analysis of the IRIS Registry Database
Anita Barikian, MD
Annual Meeting Talks
2022
Endophthalmitis After Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Inhibitors: Management and Visual Outcomes
Kunyong Xu, MD, MHSc
Annual Meeting Talks
2018
Extended Q16W Dosing Potential for Faricimab in Neovascular Age-Related Macular Degeneration (nAMD): STAIRWAY Phase 2 Trial
Philip J. Ferrone, MD, FASRS
Annual Meeting Talks
2019

Category: Pharmacology

See more